It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis.
The abstract entitled ‘133: SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTIONLTE LONG-TERM EXTENSION STUDY’ was presented at DDW 2021, May 21-23.
- What is the rationale for the use of filgotinib in ulcerative colitis? (0:11)
- What did the SELECTION induction trials teach us about the efficacy and safety of filgotinib in patients with moderate to severely active ulcerative colitis? (1:25)
- Could you give us a brief overview of the aims and design of the maintenance study? (2:30)
- What were the results and conclusions of the study? (3:18)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!